Can India’s pharmaceutical industry achieve self-reliance in APIs? by Chetan Shah, COO, Senores Pharmaceuticals
Through strong industry cooperation, significant investment, and smart policy backing, API manufacturing may become self-reliant
Through strong industry cooperation, significant investment, and smart policy backing, API manufacturing may become self-reliant
Empagliflozin and its Fixed Drug Combinations (FDCs) have been launched under the brand names Glempa, Glempa –L and Glempa-M
Amplitude Surgical is a European MedTech leader in high-quality, lower-limb orthopaedic technologies
Overall investment in the US facility is estimated around US$50 million
Biotech potential of Himalayan territories including Jammu & Kashmir, particularly their agri-biotech potential remains still under-explored
Zydus will carry out early-stage development, animal immunogenicity studies and regulatory preclinical toxicology studies for this combination vaccine
Notably, 36 female students have been placed in Production and Manufacturing roles, reflecting the growing representation of women in core biotech operations
The approval marks Venus Remedies’ strategic entry into complex generics, expanding its injectable portfolio beyond traditional formulations
Company expects to begin building four more domestic manufacturing sites this year and add 13,000 high-wage manufacturing and construction jobs in America
Subscribe To Our Newsletter & Stay Updated